This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Federico, M. Articles by Damasio, E. E. Search for Related Content PubMed PubMed Citation Articles by Federico, M. Articles by Damasio, E. E. Social Bookmarking                            What's this?

Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up

From the Oncologia Medica and Dipartimento di Scienze Igienistiche, Università di Modena e Reggio Emilia, Modena; Istituto di Ematologia "L.A. Seragnoli," Università di Bologna, Bologna; Cattedra di Ematologia, Dipartimento di Biopatologia Umana, Università "La Sapienza," Roma; Divisione di Ematologia, Ospedale Civile, Venezia-Mestre; Cattedra di Ematologia and Dipartimento di Medicina e Oncologia, Università di Pavia, Pavia; Divisione di Ematologia, Ospedale "San Martino," Genova; and Divisione di Ematologia, Ospedale "Molinette," Torino, Italy.

Address reprint requests to Massimo Federico, MD, Oncologia Medica, Università di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, 41100 Modena, Italy; email: federico{at}unimo.it

PURPOSE: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL).

PATIENTS AND METHODS: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up.

RESULTS: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin’s lymphoma in the entire cohort was 5.3 (95% CI, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR.

CONCLUSION: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.

M.F. and P.L.Z. contributed equally to preparing the manuscript.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Hisada, B. E. Chen, E. S. Jaffe, and L. B. Travis Second Cancer Incidence and Cause-Specific Mortality Among 3104 Patients With Hairy Cell Leukemia: A Population-Based Study J Natl Cancer Inst, February 7, 2007; 99(3): 215 - 222. [Abstract] [Full Text] [PDF]

				S. O. Wanko and C. de Castro Hairy Cell Leukemia: An Elusive but Treatable Disease Oncologist, July 1, 2006; 11(7): 780 - 789. [Abstract] [Full Text] [PDF]